Sihuan Pharmaceutical Holdings Group Ltd.
Quick facts
| Founded | 2001 |
|---|
Marketed products
Phase 3 pipeline
- Janagliflozin plus metformin · Diabetes
Janagliflozin is an SGLT2 inhibitor that reduces blood glucose by blocking renal glucose reabsorption, combined with metformin which decreases hepatic glucose production and improves insulin sensitivity. - Placebo/Janagliflozin · Diabetes
Janagliflozin is an SGLT2 inhibitor that blocks glucose reabsorption in the kidney, promoting urinary glucose excretion and lowering blood glucose levels.
Phase 2 pipeline
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Sihuan Pharmaceutical Holdings Group Ltd. portfolio CI brief
- Sihuan Pharmaceutical Holdings Group Ltd. pipeline updates RSS
Frequently asked questions about Sihuan Pharmaceutical Holdings Group Ltd.
What are Sihuan Pharmaceutical Holdings Group Ltd.'s marketed drugs?
Top marketed products include Anaprazole Sodium enteric-coated tablet.
What is Sihuan Pharmaceutical Holdings Group Ltd.'s pipeline?
Sihuan Pharmaceutical Holdings Group Ltd. has 2 drugs in Phase 3, 2 in Phase 2, 5 in Phase 1. Late-stage candidates include Janagliflozin plus metformin, Placebo/Janagliflozin.
When was Sihuan Pharmaceutical Holdings Group Ltd. founded?
Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001.